Split History
ETFs Holding CLDN »    CLDN Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Celladon is a clinical-stage biotechnology company focused on the development of cardiovascular gene therapy. Co.'s therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes gene therapies and small molecule compounds. Co. is evaluating its key product candidate, MYDICAR, in an international Phase 2b trial in patients with heart failure for reduced ejection fraction or HFrEF (also referred to as systolic heart failure), which it refers to as CUPID 2. Co. is also developing MYDICAR for additional indications, such as arteriovenous fistula, or AVF maturation failure, and for the treatment of patients with heart failure who are on a left-ventricular assist device. According to our CLDN split history records, CLDN has had 2 splits.
CLDN split history picture
CLDN (CLDN) has 2 splits in our CLDN split history database. The first split for CLDN took place on February 16, 2006. This was a 3 for 2 split, meaning for each 2 shares of CLDN owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. CLDN's second split took place on June 16, 2006. This was a 3 for 2 split, meaning for each 2 shares of CLDN owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.

When a company such as CLDN splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the CLDN split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CLDN shares, starting with a $10,000 purchase of CLDN, presented on a split-history-adjusted basis factoring in the complete CLDN split history. CLDN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/30/2014
End date: 03/22/2016
Start price/share: $8.18
End price/share: $1.15
Dividends collected/share: $0.00
Total return: -85.94%
Average Annual Total Return: -60.02%
Starting investment: $10,000.00
Ending investment: $1,406.22
Years: 2.14
Date Ratio
02/16/20063 for 2
06/16/20063 for 2
CLDN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CLDX Split History
CLRB Split History
CLRBW Split History
CLSN Split History
CMD Split History
CMN Split History
CNC Split History
CNDO Split History
CNMD Split History
COO Split History

Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CLDN Insider Buying

CLDN Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.